BRT functions as a PD-L1 inhibitor, acting directly and/or indirectly on PD-L1, to reduce its expression, and thereby inhibiting cancer cell proliferation and angiogenesis (Figure 9) [67]. This evidence concerns the gene CD274 and cancer.